Journal
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
Volume 9, Issue 5, Pages 655-663Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/17512433.2016.1162095
Keywords
lipid-lowering drugs; familial hypercholesterolemia; MTP inhibitors; Lomitapide; cholesterol
Categories
Funding
- Bayer HealthCare
Ask authors/readers for more resources
Lomitapide is a drug recently approved for the treatment of patients with homozygous familial hypercholesterolemia. In this article we discuss briefly the pharmacology of this drug followed by a comprehensive narrative review of the available preclinical and clinical data on its safety and efficacy. Only data published as full papers are presented, with the exception of one long-term open-label extension study, which is available only in abstract form.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available